PMID- 15178357
OWN - NLM
STAT- MEDLINE
DCOM- 20050614
LR  - 20161124
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 492
IP  - 2-3
DP  - 2004 May 25
TI  - Effects of mGlu1 and mGlu5 metabotropic glutamate antagonists to reverse morphine 
      tolerance in mice.
PG  - 137-42
AB  - Intracerebroventricular (i.c.v.) injection of phospholipase C inhibitors and 
      structurally dissimilar PKC inhibitors were shown to completely reverse morphine 
      antinociceptive tolerance in mice. Since Group I metabotropic glutamate receptors 
      (mGlu(1) and mGlu(5)) activate phospholipase C through Galpha(q) Galpha(11) 
      proteins, we hypothesized that morphine tolerance could occur through an increase 
      in mGlu(1) and mGlu(5) receptor stimulation. Seventy-two hours after implantation 
      of placebo or 75 mg morphine pellets, mice were tested in the 56 degrees C 
      warm-water tail-withdrawal test following i.c.v. injection of vehicle or test 
      drug. The mGlu(1) receptor antagonist CPCCOEt 
      (7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester) partly but 
      significantly reversed morphine tolerance. The mGlu(5) receptor antagonist MPEP 
      (2-Methyl-6-(phenylethynyl)pyridine hydrochloride) also partly reversed the 
      antinociceptive tolerance. Co-administering CPCCOEt with MPEP completely reversed 
      the tolerance. Furthermore, the mixed mGlu(1)/mGlu(5) antagonist AIDA 
      ((RS)-1-Aminoindan-1,5-dicarboxylic acid) also completely reversed the tolerance. 
      Thus, greater mGlu(1) and mGlu(5) receptor stimulation during morphine tolerance 
      may lead to persistent activation of the phosphatidylinositol cascade.
FAU - Smith, Forrest L
AU  - Smith FL
AD  - Department of Pharmacology and Toxicology, Virginia Commonwealth University 
      Medical Center, P.O. Box 980613, Richmond, VA 23298-0613, USA. flsmith1@vcu.edu
FAU - Smith, Paul A
AU  - Smith PA
FAU - Dewey, William L
AU  - Dewey WL
FAU - Javed, Ruby R
AU  - Javed RR
LA  - eng
GR  - DA-01647-26/DA/NIDA NIH HHS/United States
GR  - K05-DA-00480/DA/NIDA NIH HHS/United States
GR  - T32-DA-07027/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (1-aminoindan-1,5-dicarboxylic acid)
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Indans)
RN  - 0 (Pyridines)
RN  - 0 (Receptor, Metabotropic Glutamate 5)
RN  - 0 (Receptors, Metabotropic Glutamate)
RN  - 0 (metabotropic glutamate receptor type 1)
RN  - 76I7G6D29C (Morphine)
RN  - 7VC0YVI27Y (6-methyl-2-(phenylethynyl)pyridine)
SB  - IM
MH  - Analgesics, Opioid/pharmacology
MH  - Animals
MH  - *Drug Tolerance
MH  - Indans/pharmacology
MH  - Male
MH  - Mice
MH  - Morphine/administration & dosage/*pharmacology
MH  - Pain Measurement
MH  - Pyridines/pharmacology
MH  - Receptor, Metabotropic Glutamate 5
MH  - Receptors, Metabotropic Glutamate/*antagonists & inhibitors
MH  - Tail
EDAT- 2004/06/05 05:00
MHDA- 2005/06/15 09:00
CRDT- 2004/06/05 05:00
PHST- 2003/12/11 00:00 [received]
PHST- 2004/03/24 00:00 [revised]
PHST- 2004/03/30 00:00 [accepted]
PHST- 2004/06/05 05:00 [pubmed]
PHST- 2005/06/15 09:00 [medline]
PHST- 2004/06/05 05:00 [entrez]
AID - S0014299904003681 [pii]
AID - 10.1016/j.ejphar.2004.03.055 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2004 May 25;492(2-3):137-42. doi: 10.1016/j.ejphar.2004.03.055.